IMNR - Immune Response Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : IMNR - Immune Response

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: MJ who wrote (1499)	3/10/2005 11:13:48 AM
From: vladz	Read Replies (1) of 1510

Immune Response Posts Good Remune Data Wednesday March 9, 1:53 pm ET Immune Response Posts Positive Data for HIV Treatment Remune From Two Studies CARLSBAD, Calif. (AP) -- Biopharmaceutical company Immune Response Corp. said Wednesday that results from two European studies for Remune showed that the HIV treatment delayed virologic failure in patients taking other HIV treatments. ADVERTISEMENT Immune Response shares rose 15 cents, or 15 percent, to $1.15 in afternoon trading on the Nasdaq. In a mid-stage Spanish study following 39 patients, those given Remune were less likely to reach the failure endpoint of having HIV RNA greater than 55,000 copies per milliliter at 48 weeks. In an Italian study that followed 51 patients, those patients given Remune had stable white blood cell counts through 28 weeks of treatment in patients receiving 3 injections. White blood cell counts in those patients given saline injections or another treatment declined, the company said. Immune Response said that both studies were not powered for regulatory approval but to explore the potential utility of the treatment. The company said it will use the results to support other trials.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next